PL350993A1 - Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses - Google Patents

Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses

Info

Publication number
PL350993A1
PL350993A1 PL00350993A PL35099300A PL350993A1 PL 350993 A1 PL350993 A1 PL 350993A1 PL 00350993 A PL00350993 A PL 00350993A PL 35099300 A PL35099300 A PL 35099300A PL 350993 A1 PL350993 A1 PL 350993A1
Authority
PL
Poland
Prior art keywords
epsilon
ige
epitopes
antagonists
domain
Prior art date
Application number
PL00350993A
Other languages
English (en)
Inventor
Michael Dyson
Martin Friede
Judith Greenwood
Ellen Hewitt
Alan Lamont
Sean Mason
Roger Randall
William Gordon Turnell
Mechelen Marcelle Paulette Van
Y De Bassols Carlota Vinals
Original Assignee
Smithkline
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904405.9A external-priority patent/GB9904405D0/en
Priority claimed from GBGB9907151.6A external-priority patent/GB9907151D0/en
Priority claimed from GBGB9910537.1A external-priority patent/GB9910537D0/en
Priority claimed from GBGB9910538.9A external-priority patent/GB9910538D0/en
Priority claimed from GBGB9918603.3A external-priority patent/GB9918603D0/en
Priority claimed from GBGB9918594.4A external-priority patent/GB9918594D0/en
Priority claimed from GBGB9921047.8A external-priority patent/GB9921047D0/en
Priority claimed from GBGB9921046.0A external-priority patent/GB9921046D0/en
Priority claimed from GBGB9925619.0A external-priority patent/GB9925619D0/en
Priority claimed from GBGB9927698.2A external-priority patent/GB9927698D0/en
Application filed by Smithkline filed Critical Smithkline
Publication of PL350993A1 publication Critical patent/PL350993A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL00350993A 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses PL350993A1 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9904405.9A GB9904405D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9907151.6A GB9907151D0 (en) 1999-03-29 1999-03-29 Therapeutic antibody composition and use
GBGB9910537.1A GB9910537D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions and uses
GBGB9910538.9A GB9910538D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions ansd uses
GBGB9918603.3A GB9918603D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918594.4A GB9918594D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9921047.8A GB9921047D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody, immunogenic compositions & uses
GBGB9921046.0A GB9921046D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody composition & use
GBGB9925619.0A GB9925619D0 (en) 1999-10-29 1999-10-29 Vaccine
GBGB9927698.2A GB9927698D0 (en) 1999-11-23 1999-11-23 Therapeutic antibody

Publications (1)

Publication Number Publication Date
PL350993A1 true PL350993A1 (en) 2003-02-24

Family

ID=27579426

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00350993A PL350993A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses

Country Status (19)

Country Link
EP (1) EP1155037A1 (zh)
JP (1) JP2004538238A (zh)
KR (1) KR20020007313A (zh)
CN (1) CN1348466A (zh)
AR (1) AR029336A1 (zh)
AU (1) AU2672700A (zh)
BR (1) BR0008963A (zh)
CA (1) CA2363637A1 (zh)
CO (1) CO5210906A1 (zh)
CZ (1) CZ20013082A3 (zh)
HK (1) HK1044004A1 (zh)
HU (1) HUP0200049A2 (zh)
IL (1) IL145024A0 (zh)
MX (1) MXPA01008613A (zh)
NO (1) NO20014130L (zh)
NZ (1) NZ513679A (zh)
PL (1) PL350993A1 (zh)
TR (1) TR200102506T2 (zh)
WO (1) WO2000050460A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
JP4229704B2 (ja) * 2001-04-18 2009-02-25 ダイアックス、コープ Ｆｃ領域ポリペプチドの結合分子
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
JP2010519194A (ja) * 2007-02-15 2010-06-03 アストラゼネカ・アクチエボラーグ ＩｇＥ分子に対する結合要素
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
EP3882274A4 (en) * 2018-09-21 2022-06-29 Riken Anti-ige antibody specifically binding to membrane-bound ige antibody of ige antibody-producing b cells and method for diagnosing and treating allergic symptoms using the same
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
EP0996857B1 (en) * 1997-07-17 2009-09-09 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides

Also Published As

Publication number Publication date
HUP0200049A2 (en) 2002-05-29
IL145024A0 (en) 2002-06-30
BR0008963A (pt) 2001-11-27
AU2672700A (en) 2000-09-14
WO2000050460A1 (en) 2000-08-31
TR200102506T2 (tr) 2002-06-21
KR20020007313A (ko) 2002-01-26
CZ20013082A3 (cs) 2002-02-13
JP2004538238A (ja) 2004-12-24
MXPA01008613A (es) 2003-06-24
NZ513679A (en) 2001-09-28
NO20014130D0 (no) 2001-08-24
CA2363637A1 (en) 2000-08-31
EP1155037A1 (en) 2001-11-21
NO20014130L (no) 2001-09-13
CO5210906A1 (es) 2002-10-30
HK1044004A1 (zh) 2002-10-04
AR029336A1 (es) 2003-06-25
CN1348466A (zh) 2002-05-08

Similar Documents

Publication Publication Date Title
HUP0105490A3 (en) Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
IL154272A0 (en) The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
IL144147A0 (en) Regulators of the pct or smoothened pathway, compositions and uses related thereto
AU8729101A (en) Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
NO20025004L (no) Fremgangsmåte for fremstilling av 2,5-diketopiperaziner, 2,5- diketopiperaziner, dipeptider samt anvendelse derav
EE05107B1 (et) Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine
AU2666901A (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
PL366305A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
PL338004A1 (en) Derivatives of azetidinylpropylpiperidine, intermediate compounds and application of such derivatives as antagonists of tachykinins
EP1254140A4 (en) SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
ID19245A (id) Antagonis reseptor vitronektin, pembuatannya dan pemakaiannya
HK1043059A1 (en) Tumor necrosis factor antagonists and their use inendometriosis.
IL145024A0 (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
PL338453A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
PT964867E (pt) Antagonistas da taquicinima
GC0000142A (en) An inhibitor of the formation of soluble human cd23.
AU5565401A (en) Materials and methods for the treatment of depression
ZA200403530B (en) Chemokine receptor antagonists and methods of use thereof.
ZA200107015B (en) Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.
PL338456A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
HK1055288A1 (en) Novel aqueous composition and use of the same
NO20005856D0 (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
Kelly The Patronage of Frédéric Hartmann and the Question of'Finish'